Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 47.96% is in line with its 5-year average of 49.81%, around the middle of its 5-year range (40.28%–63.35%).
0.52% below its 12-month average of 48.21%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 59.27%.
GROSS MARGIN
47.96%
GROSS MARGIN AVG TTM
48.21%
GROSS MARGIN AVG 3Y
48.42%
GROSS MARGIN AVG 5Y
49.81%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.52%
CURRENT VS 3Y AVG
-0.95%
CURRENT VS 5Y AVG
-3.71%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+15.90%
vs the sector median at left
Market Cap
$82.47M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$82.53M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$82.59M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-39721.34%
Market Cap
$84.13M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$80.30M
Gross Margin
-736.46%
TTM Avg
-368.23%
3Y Avg
-290.99%
5Y Avg
-1574.61%
Market Cap
$79.61M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LENSAR Inc (LNSR) | $82.29M | 47.96% | 48.21% | 48.42% | 49.81% |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.47M | 100.00% | 100.00% | 100.00% | 100.00% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $82.53M | 0.00% | 0.00% | 0.00% | 0.00% |
| ProMIS Neurosciences, Inc. (PMN)vs › | $82.59M | 0.00% | 0.00% | 0.00% | -39721.34% |
| MediciNova, Inc. (MNOV)vs › | $81.22M | 7.58% | 3.79% | 26.89% | 34.60% |
| Nutriband Inc. (NTRB)vs › | $81.20M | 33.14% | 30.24% | 34.48% | 35.28% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | 0.00% | 0.00% | 0.00% | 0.00% |
| Humacyte, Inc. (HUMA)vs › | $80.30M | -736.46% | -368.23% | -290.99% | -1574.61% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | 0.00% | 0.00% | 0.00% | 0.00% |
| Citius Oncology, Inc. (CTOR)vs › | $79.03M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
48.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 59.27% |
| 2026-03-31 | 47.53% |
| 2025-12-31 | 43.29% |
| 2025-09-30 | 40.56% |
| 2025-06-30 | 50.41% |
| 2025-03-31 | 50.32% |
| 2024-12-31 | 42.48% |
| 2024-09-30 | 46.28% |
| 2024-06-30 | 52.08% |
| 2024-03-31 | 50.91% |
| 2023-12-31 | 40.28% |
| 2023-09-30 | 49.79% |
| 2023-06-30 | 56.29% |
| 2023-03-31 | 52.35% |
| 2022-12-31 | 63.35% |
| 2022-09-30 | 50.19% |
| 2022-06-30 | 60.86% |
| 2022-03-31 | 50.24% |
| 2021-12-31 | 50.17% |
| 2021-09-30 | 46.55% |
| 2021-06-30 | 56.27% |
| 2021-03-31 | 55.29% |
| 2020-12-31 | 56.31% |
| 2020-09-30 | 54.53% |
| 2020-06-30 | 38.56% |
| 2020-03-31 | 60.41% |
| 2019-12-31 | 55.14% |
| 2019-09-30 | 40.59% |
| 2019-06-30 | 37.78% |
| 2019-03-31 | 37.78% |
